Merck In-Licenses Inspirna’s Ompenaclid for Advanced Colorectal Cancer, Eyes Market Potential
Germany-based Merck (NYSE: MRK) has in-licensed the potential first-in-class candidate ompenaclid from U.S. firm Inspirna,...
Boehringer Ingelheim Teams Up with 3T Biosciences for Next-Gen T-Cell Cancer Therapies
German pharmaceutical leader Boehringer Ingelheim (BI) has entered into a new agreement with U.S.-based 3T...
Novo Nordisk Expands U.S. Ties, Collaborates with Flagship Pioneering on Cardiometabolic Advances
Danish pharmaceutical giant Novo Nordisk (NYSE: NVO) is advancing its U.S. partnerships by joining forces...
Menarini’s Stemline Signs $500M+ License with Insilico for Cancer Drug Candidate
Italy’s Menarini Group, through its subsidiary Stemline Therapeutics, has entered an exclusive license agreement with...
Genrix Bio Seeks China Approval for New Xeligekimab Use in Axial Spondyloarthritis
Chongqing Genrix Biopharmaceutical Co., Ltd. (SHA: 688443), a biopharmaceutical company based in China, has submitted...
Shanghai Pharmaceuticals’ Subsidiary Reprimanded Again for Monopolisitic Pricing of Polymyxin B Sulfate
The Shanghai Administration for Market Regulation (AMR) bureau has once again reprimanded SHP No.1 Biomedical...
Akeso Biopharma Submits New Indication Application for Cadonilimab in Gastric Cancer Treatment
Akeso Biopharma (HKG: 9926), a leading biopharmaceutical company based in China, has announced the submission...
JW Therapeutics Secures NMPA Review for CAR-T Therapy in Mantle Cell Lymphoma
JW Therapeutics (HKG: 2126), a Chinese biopharmaceutical company, has announced that it has submitted an...
China’s Ministry of Education Launches Professional Guidelines for Healthcare Talent Training
The Ministry of Education (MoE) in China has issued a Notice outlining the “Professional Guidelines...
Jiangsu Hengrui Pharmaceuticals Advances Novel Cancer Therapies with NMPA Clinical Trial Approval
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has received approval from the National Medical Products...
Suzhou Elite Analytical Instruments Secures Over $14 Million in Initial Funding Round
Suzhou Elite Analytical Instruments Co., Ltd, a leading specialist in liquid chromatography based in China,...
Jiangsu Vcare PharmaTech Submits NDA to US FDA for Vicagrel, a P2Y12 Receptor Antagonist
Jiangsu Vcare PharmaTech Co., Ltd, a Chinese pharmaceutical company, has submitted a New Drug Application...
Allorion Therapeutics and Avenzo Seal Deal for Global Rights to CDK2 Inhibitor
China-based Allorion Therapeutics has entered into a licensing agreement with Avenzo Therapeutics Inc., granting the...
BMS’s Sotyktu, First TYK2 Inhibitor, Hits Chinese Market
US pharmaceutical giant Bristol Myers Squibb (BMS, NYSE: BMY) has announced the market launch of...
China’s National People’s Congress Approves Stricter Punishments for Sector-Specific Bribery
The 7th meeting of the 14th National People’s Congress Standing Committee has passed the latest...
Daiichi Sankyo and Esperion Therapeutics Amend Collaboration on Antilipidemic Drugs
Daiichi Sankyo (TYO: 4568)’s European subsidiary, a Japanese pharmaceutical company, has entered into a collaboration...
Shanghai BDgene Technology’s Thalassemia Gene Therapy BD211 Clears NMPA for Clinical Trials
Shanghai BDgene Technology Co., Ltd, a specialist in gene therapy, has received clinical trial approval...
Belief BioMed Group Initiates Clinical Study for Hemophilia A Gene Therapy BBM-H803 in China
Belief BioMed Group, a Shanghai-based gene therapy specialist, has announced the first subject dosing in...
IASO Biotherapeutics and Umoja Biopharma Join Forces for Innovative Cell and Gene Therapies Development
IASO Biotherapeutics, a China-based company, and Umoja Biopharma, a California-headquartered developer of off-the-shelf cell therapies,...
Full-Life Technologies Secures USD 63.3 Million in Financing to Boost Radiotherapeutics Pipeline and Manufacturing
Full-Life Technologies Ltd, a global radiotherapeutics company with a presence in Belgium, Germany, and China,...